The Myeloma Canada Research Network Announces the Activation of
MCRN 004 – the LAURENTIANS Trial
The first site for the MCRN 004 – the LAURENTIANS Trial, was activated on December 5, 2017. This study will not only provide access to daratumumab (Darzalex®) for eligible patients participating in the trial across the country, but it will also answer the question of how to optimize the use of expensive drug combinations using a rational and cost-effective approach.
To learn more about this innovative clinical trial, watch the video below.
Participating sites for the LAURENTIANS Trial*

  • Calgary, AB – Tom Baker Cancer Centre
  • Edmonton, AB – Cross Cancer Institute
  • Halifax, NS – Queen Elizabeth II Health Sciences Centre
  • Hamilton, ON – Juravinski Cancer Centre
  • Ottawa, ON – The Ottawa Hospital
  • Saint John, NB – Saint John Regional Hospital
  • Saskatoon, SK – Saskatoon Cancer Centre
  • Surrey, BC – BCCA Fraser Valley Centre
  • Toronto, ON – Princess Margret Cancer Centre
  • Winnipeg, MB – CancerCare Manitoba

* Please note that this list is subject to change and site activation dates may vary.
Redefining and Revolutionizing Research

As a patient organization, Myeloma Canada promotes its commitment to patient-focused clinical research in collaboration with the Myeloma Canada Research Network (MCRN). This unique network of world-class Canadian myeloma researchers brings Canadian-designed clinical trials to patients and promotes the sharing of scientific data and expertise amongst its members. Their overarching goal is to help Canadian patients gain access to new therapies in an accelerated manner and improve overall outcomes.

For more information on the MCRN and other clinical trials that are recruiting patients, click here .
Spotlight on Karen Bjarnason, a 22-Year Surviving Patient from British Columbia
“I have hope again”
Myeloma Canada Announces the Winner of the 2017 Myeloma Canada Marion State Memorial Nursing Award
Cathy Foster is a Primary Care Nurse in Hematology at the Joseph Brant Hospital (JBH) Cancer Clinic in Burlington, Ontario, and has dedicated 25 years caring for hematology/oncology patients, mentoring nurses, coordinating with the pharmacy team and most importantly, assisting oncologists and hematologists.
Upcoming Events
Myeloma Canada National Conference for Patients, Caregivers and the Medical Community

May 12-13, 2018 –
Radisson Hotel Vancouver Airport

Stay tuned for details on the upcoming 2018 Myeloma Canada National Conference in Vancouver, BC. This two-day conference is an opportunity to get updates on the latest news in myeloma research, treatments and disease management. This must-attend meeting will include practical workshops, as well as informational presentations from leading myeloma experts and an opportunity to meet and exchange with other patients, caregivers and health care professionals.
2018 Myeloma Canada InfoSessions

In addition to the National Conference in May 2018, Myeloma Canada is planning 8 patient and caregiver InfoSessions (dates to be announced) in the following communities:

  • Gatineau, QC
  • Grande Prairie, AB
  • Moncton, NB
  • Oshawa, ON
  • Prince George, BC
  • Rimouski, Quebec
  • Sudbury, ON
  • Sydney, NS
Highlights from the 2017 Annual ASH Meeting in Atlanta
The American Society of Hematology (ASH) Annual Meeting, the world’s most important gathering of hematologists, showcases thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Many of our MCRN researchers presented their abstracts orally or through posters.
Donate Securities Before the End of the Tax Year
Supporting charitable organizations is a valued and respected part of the Canadian society. To encourage the gift of shares, the government has simplified the process by removing capital gains tax on donated shares and stocks. You can donate your shares to Myeloma Canada with a simple electronic transfer. Once received, we will immediately issue a tax receipt for the fair market value. If deductions cannot be used for that calendar year, you can carry the remainder over the next five years.

Did You Know?
If shares have appreciated in value at the time of transfer to Myeloma Canada, you pay no tax on the gain in value and still receive a charitable tax receipt for the highest value of the shares.
Giving in Shares to Myeloma Canada has its Benefits
Please note during the holidays Myeloma Canada's hours of operation will be limited between December 23rd, 2017, to January 5th, 2018. During this time, you may contact us anytime by email at A member from our team will contact you within 48 hours.